echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fosun Pharma's new crown mRNA vaccine has been activated clinically 72 subjects have been vaccinated.

    Fosun Pharma's new crown mRNA vaccine has been activated clinically 72 subjects have been vaccinated.

    • Last Update: 2020-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The Clinical Phase I pilot program in China recruited 144 healthy subjects to assess the safety and immunogenicity of the candidate vaccine and determine dose selection.
    in the first phase of clinical studies, the first group of subjects inoculated will be healthy adults (18-55 years old), followed by healthy older adults (over 55 years of age).
    as part of a two-dose cohort design, subjects will be given two injections, 21 days apart, with 10 micrograms or 30 micrograms of candidate vaccine or placebo. The selection of
    dose range is based on early data from previous clinical trials in Germany and the United States.
    subjects will be tested at the Phase I clinical base in Taizhou, Jiangsu Province.
    the study will be conducted in accordance with regulatory approval procedures in China and further confirm that the safety and immunogenicity observed in subjects in The German and U.S. trials are comparable to those observed in China.
    ongoing clinical studies in Germany and the United States will continue to support research in China.
    Clinical studies in China will be the first to evaluate the nucleoside-modified messenger RNA (modRNA) candidate BNT162b1, one of two vaccines based on BioNTech proprietary mRNA technology and has been FDA fast-track certified, following ongoing phase 1/2 studies in Germany and the United States.
    , bnT162b2, another FDA fast-track-certified candidate, is being evaluated in a global Phase 2b/3 clinical trial by BioNTech and Pfizer, which began July 27.
    Fosun Pharma and BioNTech plan to continue to explore and advance the possibility of other candidate vaccines based on BioNTech proprietary mRNA technology for clinical trials in China.
    during clinical development, BioNTech will provide clinical availability of vaccines through its GMP-certified mRNA manufacturing facilities in Europe.
    if the vaccine is licensed for sale in the future, Fosun Pharma will exclusively commercialize COVID-19 vaccine products based on the BioNTech mRNA technology platform in Chinese mainland and Hong Kong, Macao and Taiwan.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.